INT19108

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1985
Last Reported 1991
Negated 0
Speculated 0
Reported most in Abstract
Documents 2
Total Number 3
Disease Relevance 1.70
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IFNA2) extracellular region (IFNA2) cell-cell signaling (IFNA2)
IFNA2 (Homo sapiens)
Pain Link Frequency Relevance Heat
abdominal pain 3 80.84 Quite High
Disease Link Frequency Relevance Heat
Toxicity 4 99.60 Very High Very High Very High
Ovarian Cancer 6 98.52 Very High Very High Very High
Syncope 1 85.64 High High
Abdominal Pain 3 80.84 Quite High
Influenza Virus Infection 1 77.88 Quite High
Leukemia 2 75.00 Quite High
Recurrence 2 75.00 Quite High
Disease 3 74.96 Quite High
Disease Progression 4 74.32 Quite High
Residual Neoplasm 2 68.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Fourteen patients with persistent epithelial ovarian cancer documented at second look laparotomy after combination chemotherapy were treated with 146 cycles of alpha-recombinant interferon (rIFN-alpha 2) administered i.p.
Positive_regulation (treated) of Negative_regulation (cycles) of rIFN-alpha 2 associated with ovarian cancer
1) Confidence 0.49 Published 1985 Journal Cancer Res. Section Abstract Doc Link 4028027 Disease Relevance 0.37 Pain Relevance 0
Fourteen patients with persistent epithelial ovarian cancer documented at second look laparotomy after combination chemotherapy were treated with 146 cycles of alpha-recombinant interferon (rIFN-alpha 2) administered i.p.
Positive_regulation (treated) of Negative_regulation (cycles) of alpha-recombinant interferon associated with ovarian cancer
2) Confidence 0.49 Published 1985 Journal Cancer Res. Section Abstract Doc Link 4028027 Disease Relevance 0.37 Pain Relevance 0
Continuation therapy including rIFN-alpha pulse was well tolerated in the remaining children; only one patient required rIFN-alpha dosage reduction (for CNS toxicity). rIFN-alpha toxicity did not necessitate reductions in doses of standard chemotherapy agents or significant delays in therapy.
Positive_regulation (required) of Negative_regulation (reduction) of rIFN-alpha associated with toxicity
3) Confidence 0.18 Published 1991 Journal J. Clin. Oncol. Section Abstract Doc Link 2016619 Disease Relevance 0.96 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox